Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
The company references a proprietary platform designed to enhance drug delivery for radiation sensitization, indicating a drug delivery platform.
|
$1.45M |
$1.36
+2.26%
|
|
BIAF
bioAffinity Technologies, Inc.
The business focuses on oncology diagnostics (early detection of lung cancer).
|
$1.38M |
$1.46
+2.10%
|
|
GRTX
Galera Therapeutics, Inc.
Company directly develops oncology therapeutics, including its NOS pan-inhibitor and SOD mimetics for cancer indications.
|
$1.15M |
$0.02
|
|
CDT
CDT Equity Inc.
AZD1656/AZD5658 are small-molecule therapeutics licensed for development.
|
$792299 |
$2.09
+13.59%
|
|
CMND
Clearmind Medicine Inc.
CMND-100 is an oral small-molecule therapeutic candidate, categorizing the company under Oral Small Molecule Therapeutics.
|
$617181 |
$0.15
-7.12%
|
|
INIS
International Isotopes Inc.
Core product: INIS manufactures radiopharmaceutical drugs (I-131) used for diagnostic imaging and therapy.
|
$580409 |
$0.06
|
|
SLRX
Salarius Pharmaceuticals, Inc.
Salarius operates as a clinical-stage biotech focused on oncology therapies (e.g., LSD1 inhibitor seclidemstat) and develops cancer treatments.
|
$471478 |
$0.92
+4.23%
|
|
ZVSA
ZyVersa Therapeutics, Inc.
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, classifiable as Monoclonal Antibody Therapeutics.
|
$378551 |
$0.14
|
|
NLSP
NLS Pharmaceutics AG
Kadimastem's allogeneic cell-therapy platform (IsletRx, AstroRx) and NLSP's merger create a clear Cell Therapy business line.
|
$377531 |
$0.79
-74.81%
|
|
RGBP
Regen BioPharma, Inc.
RGBP focuses on oncology/s Cancer immunotherapy and regenerative medicine, aligning with Biotech - Oncology.
|
$306080 |
$0.01
|
|
LADX
LadRx Corporation
LadRx is a biotechnology company focused on oncology drug development.
|
$64362 |
$0.13
|
|
CERO
CERo Therapeutics Holdings, Inc.
CER-T is a cell therapy platform with lead candidate CER-1236, indicating direct cell-based therapeutic products.
|
$28861 |
$0.10
+38.00%
|
|
EMMA
Emmaus Life Sciences, Inc.
Endari is an oral small-molecule therapeutic (L-glutamine) marketed by Emmaus Life Sciences for sickle cell disease.
|
$13548 |
$0.01
|
|
PLRZ
Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
|
$8442 |
$0.52
-11.07%
|
|
SMFL
Smart for Life, Inc.
SMFL owns manufacturing facilities (BSNM and DSO) and provides contract manufacturing for branded and contract-made nutraceutical products.
|
$57 |
$0.02
|
|
NCNA
NuCana plc
NuCana is a clinical-stage oncology biotech focusing on cancer therapeutics (NUC-3373 and NUC-7738).
|
N/A |
$3.97
+3.12%
|
Showing page 25 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
